Treatments and outcomes for patients with myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) scores at the Huntsman Cancer Institute (HCI)

• Published in: Journal of clinical oncology Vol. 39; no. 15_suppl; p. e19034
• Main Authors: Willis, Connor, Tan, Malinda Sunnita, Bauer, Hillevi, Au, Trang H., Tantravahi, Srinivas Kiran, Gilreath, Jeffrey, Kovacsovics, Tibor, Cao, Xiting, Sadek, Islam, Stenehjem, David D.
• Format: Journal Article
• Language: English
• Published: Wolters Kluwer Health 20.05.2021

e19034Background: IPSS-R is used to classify risk of disease progression and guide treatment decisions for patients with MDS. Recent data shows mutational profiling may improve the prognostic stratification of MDS. Minimal real-world evidence exists for this population. Methods: A retrospective coho...